Prescription DrugsVaccine

Menactra Inj.


  • 0.5-milliliter (mL) dose of MenQuadfi® to contain 10 µg each of meningococcal A, C, W, and Y polysaccharides conjugated to approximately 55 µg of tetanus toxoid protein carrier
  • Active immunization to prevent invasive meningococcal
    disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra
    is approved for use in individuals 9 months through 55 years of age
Print Contact us
Go to list
Go to list
맨위로